Autonomix Medical (AMIX) investor relations material

Executive summary

• Focused on developing catheter-based neural sensing and RF ablation technology for nerve-targeted therapies, initially for pancreatic cancer pain, with potential for broader applications in visceral pain and cardiovascular disease.

• No product revenue generated; company remains in development stage and continues to incur significant operating losses.

• Early clinical studies showed variable outcomes, leading to a pause in enrollment for further evaluation and refinement.

Financial highlights

• Net loss for the quarter ended June 30, 2026 was $2.7 million, compared to $3.3 million for the same period in 2025.

• Operating expenses decreased 19% year-over-year to $2.8 million, driven by lower R&D and G&A costs.

• Cash and cash equivalents were $3.5 million as of June 30, 2026, down from $7.0 million at March 31, 2026.

• No revenue reported for the quarter.

Outlook and guidance

• Current cash resources are expected to fund operations into, but not beyond, the first calendar quarter of 2027.

• Additional financing of $25–$30 million will be required to reach commercialization of the first indication.

• Company recognizes substantial doubt about its ability to continue as a going concern within one year of the financial statement issuance.